Citations

Showing 10 of 108162 citations.

Driving genotype treatment options down the right path(way)
Ross, Owen A. , Ross, Owen A , Mata, Ignácio F.

Mayo Clinic

Movement Disorders | October 25, 2019 | Volume: 34 | Issue: 12 | Pages: 1811-1813

10.1002/mds.27893 | PMID 31654424 Get It

Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review
Barra, Sérgio , Providência, Rui , Narayanan, Kumar , Boveda, Serge , Duehmke, Rudolf , Garcia, Rodrigue , Leyva, Francisco , Roger, Véronique L. , Jouven, Xavier , Agarwal, Sharad , Levy, Wayne C. , Marijon, Éloi , Providencia, Rui , Garcia, Rodrigue , Boveda, Serge

Mayo Clinic

European Heart Journal | October 25, 2019 | Volume: 41 | Issue: 21 | Pages: 1976-1986

10.1093/eurheartj/ehz773 | PMID 31750896 Get It

Abstract Aims While data from randomized trials suggest a declining incidence of sudden cardiac death (SCD) among heart failure patients, the extent to which such a trend is present among patients with cardiac resynchronization therapy (CRT) has not been evaluated. We therefore assessed changes in SCD incidence, and associated factors, in CRT recipients over the last 20 years. Methods and results Literature search from inception to 30 April 2018 for observational and randomized studies involving CRT patients, with or without defibrillator, providing specific cause-of-death data. Sudden cardiac death was the primary endpoint. For each study, rate of SCD per 1000 patient-years of follow-up was calculated. Trend line graphs were subsequently constructed to assess change in SCD rates over time, which were further analysed by device type, patient characteristics, and medical therapy. Fifty-three studies, comprising 22 351 patients with 60 879 patient-years of follow-up and a total of 585 SCD, were included. There was a gradual decrease in SCD rates since the early 2000s in both randomized and observational studies, with rates falling more than four-fold. The rate of decline in SCD was steeper than that of all-cause mortality, and accordingly, the proportion of deaths which were due to SCD declined over the years. The magnitude of absolute decline in SCD was more prominent among CRT-pacemaker (CRT-P) patients compared to those receiving CRT-defibrillator (CRT-D), with the difference in SCD rates between CRT-P and CRT-D decreasing considerably over time. There was a progressive increase in age, use of beta-blockers, and left ventricular ejection fraction, and conversely, a decrease in QRS duration and antiarrhythmic drug use. Conclusion Sudden cardiac death rates have progressively declined in the CRT heart failure population over time, with the difference between CRT-D vs. CRT-P recipients narrowing considerably.
Imaging Findings of Ileal Inflammation at Computed Tomography and Magnetic Resonance Enterography: What do They Mean When Ileoscopy and Biopsy are Negative?
Nehra, Avinash , Sheedy, Shannon P. , Wells, Michael , VanBuren, Wendaline M. , Deepak, Parakkal , Lee, Yong S. , Bruining, David H. , Fletcher, Joel G. , Nehra, Avinash K, Wells, Michael L, Hansel, Stephanie L. , Fletcher, Joel G , Deepak, Parakkal

Mayo Clinic

Journal of Crohn's and Colitis | October 25, 2019 | Volume: 14 | Issue: 4 | Pages: 455-464

10.1093/ecco-jcc/jjz122 | PMID 31960900 Get It

Abstract Background and Aims Our goal was to determine the importance of ileal inflammation at computed tomography or magnetic resonance enterography in Crohn’s disease patients with normal ileoscopy. Methods Patients with negative ileoscopy and biopsy within 30 days of CT or MR enterography showing ileal inflammation were included. The severity [0–3 scale] and length of inflammation within the distal 20 cm of the terminal ileum were assessed on enterography. Subsequent medical records were reviewed for ensuing surgery, ulceration at ileoscopy, histological inflammation, or new or worsening ileal inflammation or stricture on enterography. Imaging findings were classified as: Confirmed Progression [subsequent surgery or radiological worsening, new ulcers at ileoscopy or positive histology]; Radiologic Response [decreased inflammation with medical therapy]; or Unlikely/Unconfirmed Inflammation. Results Of 1471 patients undergoing enterography and ileoscopy, 112 [8%] had imaging findings of inflammation with negative ileoscopy, and 88 [6%] had negative ileoscopy and ileal biopsy. Half [50%; 44/88] with negative biopsy had moderate/severe inflammation at enterography, with 45%, 32% and 11% having proximal small bowel inflammation, stricture or fistulas, respectively. Two-thirds with negative biopsy [67%; 59/88] had Confirmed Progression, with 68%, 70% and 61% having subsequent surgical resection, radiological worsening or ulcers at subsequent ileoscopy, respectively. Mean length and severity of ileal inflammation in these patients was 10 cm and 1.6. Thirteen [15%] patients had Radiologic Response, and 16 [18%] had Unlikely/Unconfirmed Inflammation. Conclusion Crohn’s disease patients with unequivocal imaging findings of ileal inflammation at enterography despite negative ileoscopy and biopsy are likely to have active inflammatory Crohn’s disease. Disease detected by imaging may worsen over time or respond to medical therapy.
After-Hours EEG: Relative Value of Emergent Routine Versus Prolonged EEG Recordings
Singh, Jaysingh , Alwaki, Abdulrahman, Singh, Priti , Britton, Jeffrey, Britton, Jeffrey W. , Singh, Priti

Mayo Clinic

Journal of Clinical Neurophysiology | October 25, 2019 | Volume: 36 | Issue: 1 | Pages: 32-35

10.1097/wnp.0000000000000529 | PMID 30608366 Get It

Objective: After-hours EEG is increasingly used in hospital patients. Although the detection of seizures and interictal epileptiform discharges has been shown to be higher with prolonged EEG (pEEG) than routine-duration EEG, the relative value for particular indications can inform utilization. Method: The Mayo EEG Report System was queried for after-hours emergent routine EEG (ErEEG) and pEEG performed between January 2015 and June 2015. Total 296 after-hours ErEEG were identified, of which 140 converted into pEEG were included in the study for direct comparison of two modalities. Indications were categorized as: mental status changes, recent seizures rule out continued nonconvulsive seizures, spells, and prognosis after anoxic brain injury. Categorical data were analyzed using the McNemar and Fisher exact tests; a P value of 0.05 was considered significant. Result: Prolonged EEG was superior to ErEEG for detection of interictal epileptiform discharges (61 vs. 48/140, P = 0.004) and seizures (29 vs. 17/140, P = 0.012). Seizure detection was greater for pEEG than ErEEG for the indication of evaluating for subclinical seizures after recent observed clinical seizures (14/41 [34.1%] versus 4/41 [9.8%], P = 0.002). There was no significant difference between modalities for seizure detection in patients undergoing evaluation of spells or mental status changes without previous observed seizures. Detection of seizures on pEEG was higher for recordings greater than 24 hours (8/46, 17%, P = 0.014) and 48 hours (19/26, 73%, P < 0.001) than recordings less than 24 hours (2/68, 3%). Seizure detection was higher with pEEG in comatose patients than ErEEG (17/51, 33% vs. 12/89, 13%; P = 0.009). Conclusions: Increased value was demonstrated for pEEG over ErEEG in patients undergoing evaluation after observed recent clinical seizures and for coma. No significant difference was found between ErEEG and pEEG for seizure detection in the relatively small subgroups of patients with mental status changes other than coma and without preceding seizure or spells.
Carbo-loading in Coccidioides spp.: a quantitative analysis of CAZyme abundance and resulting glycan populations
Mitchell, Natalie M., Lake, Douglas F. , Grys, Thomas E.

Mayo Clinic

Glycobiology | October 25, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/glycob/cwz092 | PMID 31691790 Get It

Abstract Coccidioides spp. are important pneumonia-causing pathogens of the American southwest, but little is known about their glycobiology and how their glycosylations differ from other pneumonia-causing fungi. There is mounting preliminary evidence to suggest genus or even species-specific glycosylations in the fungal kingdom due to the presence of unique Carbohydrate-Active Enzymes (CAZymes) in fungal genomes (Deshpande and others 2008; Karkowska-Kuleta and Kozik 2015). If Coccidioides spp.-specific glycans can be identified, it may be possible to exploit these differences to develop more specific diagnostic approaches and more effective therapeutics. Herein we i) mined Coccidioides spp. and other pathogenic fungal genomes to identify CAZymes specific for Coccidiodes spp., ii) proteomically determined the Coccidioides spp. “CAZome” produced in vivo and in vitro, and iii) utilized glycomics to differentiate Coccidioides genus-specific N-glycans from other pathogenic fungi. As far as we are aware, this is the first proteomic and glycomic comparison of the N-glycomes and CAZomes of different fungal genera during infection in human hosts.
Infographic. Can even experienced orthopaedic surgeons predict who will benefit from surgery when patients present with degenerative meniscal tears? A survey of 194 orthopaedic surgeons who made 3880 predictions
Bloembergen, Coen H. , Graaf, Victor A. van de , Virgile, Adam , Noorduyn, Julia C. A. , Saris, Daniël B.F. , Poolman, Rudolf W. , van de Graaf, Victor A , Saris, Daniel Bf, Willigenburg, Nienke Willemien , Harris, Ian Andrew

Mayo Clinic

British Journal of Sports Medicine | October 25, 2019 | Volume: 54 | Issue: 9 | Pages: 556-557

10.1136/bjsports-2019-101502 | PMID 31653776 Get It

322.5: Impact of a face procurement on intermediate solid organ outcomes.
Rogers, Meg, Amer, Hatem , Gunderson, Susan, Amer, Hatem , Mardini, Samir

Mayo Clinic

Transplantation | October 25, 2019 | Volume: 103 | Issue: 11S | Pages: S69-S69

10.1097/01.tp.0000611944.00511.3d Get It

Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma
Jacobus, Susanna , Weiss, Matthias , Kumar, Shaji , Orlowski, Robert Z. , Kaufman, Jonathan L. , Yacoub, Abdulraheem M., O’Brien, Timothy, Matous, Jeffrey, Anderson, Daniel M. , Emmons, Robert, Mahindra, Anuj, Dhodapkar, Madhav V. , Orlowski, Robert Z. , Kaufman, Jonathan L , Lonial, Sagar , Fonseca, Rafaël , Yacoub, Abdulraheem , Buadi, Francis K. , Wagner, Lynne I. , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | October 25, 2019 | Volume: 38 | Issue: 11 | Pages: 1126-1137

10.1200/jco.19.01740 | PMID 31652094 Get It

PURPOSE Observation is the current standard of care for smoldering multiple myeloma. We hypothesized that early intervention with lenalidomide could delay progression to symptomatic multiple myeloma. METHODS We conducted a randomized trial that assessed the efficacy of single-agent lenalidomide compared with observation in patients with intermediate- or high-risk smoldering multiple myeloma. Lenalidomide was administered orally at a dose of 25 mg on days 1 to 21 of a 28-day cycle. The primary end point was progression-free survival, with disease progression requiring the development of end-organ damage attributable to multiple myeloma and biochemical progression. RESULTS One hundred eighty-two patients were randomly assigned—92 patients to the lenalidomide arm and 90 to the observation arm. Median follow-up is 35 months. Response to therapy was observed in 50% (95% CI, 39% to 61%) of patients in the lenalidomide arm, with no responses in the observation arm. Progression-free survival was significantly longer with lenalidomide compared with observation (hazard ratio, 0.28; 95% CI, 0.12 to 0.62; P = .002). One-, 2-, and 3-year progression-free survival was 98%, 93%, and 91% for the lenalidomide arm versus 89%, 76%, and 66% for the observation arm, respectively. Only six deaths have been reported, two in the lenalidomide arm versus four in the observation arm (hazard ratio for death, 0.46; 95% CI, 0.08 to 2.53). Grade 3 or 4 nonhematologic adverse events occurred in 25 patients (28%) on lenalidomide. CONCLUSION Early intervention with lenalidomide in smoldering multiple myeloma significantly delays progression to symptomatic multiple myeloma and the development of end-organ damage.
Smoking cessation is associated with lower disease activity and predicts cardiovascular risk reduction in rheumatoid arthritis patients
Roelsgaard, Ida Kristiane , Ikdahl, Eirik , Rollefstad, Silvia , Wibetoe, Grunde , Riel, Piet L. C. M. van , Gabriel, Sherine E., Douglas, Karen, Wållberg‐Jonsson, Solveig , Dessein, Patrick H , Tsang, Linda , Hitchon, Carol , Pascual‐Ramos, Virginia , Contreras-Yáñez, Irazú , Sfikakis, Petros P. , González‐Gay, Miguel Á. , Crowson, Cynthia S. , Gabriel, Sherine, Gonzalez-Gay, Miguel A , Esbensen, Bente Appel , Kitas, George D. , Kvien, Tore Kristian , Rantapää‐Dahlqvist, Solbritt , Karpouzas, George , El‐Gabalawy, Hani , Semb, Anne Grete

Mayo Clinic

Rheumatology | October 25, 2019 | Volume: 59 | Issue: 8 | Pages: 1997-2004

10.1093/rheumatology/kez557 | PMID 31782789 Get It

Abstract Objectives Smoking is a major risk factor for the development of both cardiovascular disease (CVD) and RA and may cause attenuated responses to anti-rheumatic treatments. Our aim was to compare disease activity, CVD risk factors and CVD event rates across smoking status in RA patients. Methods Disease characteristics, CVD risk factors and relevant medications were recorded in RA patients without prior CVD from 10 countries (Norway, UK, Netherlands, USA, Sweden, Greece, South Africa, Spain, Canada and Mexico). Information on CVD events was collected. Adjusted analysis of variance, logistic regression and Cox models were applied to compare RA disease activity (DAS28), CVD risk factors and event rates across categories of smoking status. Results Of the 3311 RA patients (1012 former, 887 current and 1412 never smokers), 235 experienced CVD events during a median follow-up of 3.5 years (interquartile range 2.5–6.1). At enrolment, current smokers were more likely to have moderate or high disease activity compared with former and never smokers (P &lt; 0.001 for both). There was a gradient of worsening CVD risk factor profiles (lipoproteins and blood pressure) from never to former to current smokers. Furthermore, former and never smokers had significantly lower CVD event rates compared with current smokers [hazard ratio 0.70 (95% CI 0.51, 0.95), P = 0.02 and 0.48 (0.34, 0.69), P &lt; 0.001, respectively]. The CVD event rates for former and never smokers were comparable. Conclusion Smoking cessation in patients with RA was associated with lower disease activity and improved lipid profiles and was a predictor of reduced rates of CVD events.
Conducting Human-Centered Building Science at the Well Living Lab
Aristizabal, Sara , Porter, Paige , Clements, Nicholas , Campanella, Carolina , Zhang, Rongpeng , Hovde, Kevin , Lam, Chi Hin , Lam, Chi

Mayo Clinic

Technology|Architecture + Design | October 25, 2019 | Volume: 3 | Issue: 2 | Pages: 161-173

10.1080/24751448.2019.1640535 Get It